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Screening of immunocompromised patients at risk of strongyloidiasis in western Turkey
using ELISA and real-time PCR
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Background/aim: Strongyloides stercoralis causes life-threatening hyperinfection or disseminated strongyloidiasis in
immunocompromised patients such as HIV-positive, organ transplantation, and cancer patients. This study investigated the presence of
strongyloidiasis in immunocompromised patients for the first time in Turkey.
Materials and methods: Serum and stool samples were collected from 108 patients (25.9% of them were chronic renal failure and 74.1%
were renal transplantation patients) who were admitted to Ege University Medical School in İzmir, located in western Turkey. Serum
samples were analyzed by ELISA (DRG, Germany) and the presence of 18S rRNA gene of S. stercoralis was detected in stool samples by
real-time PCR.
Results: The analysis of serum samples showed that only one patient was anti-S. stercoralis IgG antibody and real-time PCR positive
(0.92%). The patient was treated twice with albendazole (400 mg/day for 3 days) at 2-week intervals. Follow up real-time PCR was
negative and the patient became seronegative 6 months after the initial diagnosis.
Conclusion: This screening showed that the prevalence of strongyloidiasis in this small group of patients who were at risk of
strongyloidiasis was 0.92%. Overall, the results showed that more systematic studies are required in Turkey to show the prevalence of
strongyloidiasis.
Key words: Strongyloides stercoralis, ELISA, real-time PCR, diagnosis, Turkey

1. Introduction
Strongyloidiasis is a parasitic disease caused by
Strongyloides stercoralis and Strongyloides fuelleborni.
Strongyloidiasis is transmitted through contact with
contaminated soil and is endemic in tropical and
subtropical regions (1). According to the World Health
Organization (WHO), 30–100 million people are infected
by Strongyloides spp. Moreover, it is stated that most
of these cases are associated with immunosuppressive
diseases, organ transplants, and hematological
malignancies (2).
In immunocompromised patients, S. stercoralis
leads to severe strongyloidiasis, causing life-threatening
infection by dissemination and hyperinfection. S.
fuelleborni, another species of the same genus, occurs
sporadically and has globally minor importance because
of geographical restriction (3,4).
* Correspondence: mert.doskaya@ege.edu.tr

Generally, strongyloidiasis is characterized by chronic
infection and can be asymptomatic for decades in healthy
individuals (2). However, severe strongyloidiasis may
also develop when the immune system of asymptomatic
individuals is debilitated. Therefore, before initiating immune
suppressive treatment, screening for strongyloidiasis can be
performed in these patients.
The routine diagnosis of strongyloidiasis depends mainly
on stool culture and microscopic, serologic, and molecular
assays but none of these assays are regarded as the gold
standard (2). In addition, it is known that a combination of
diagnostic procedures improves sensitivity and specificity
(5,6).
Prevalence rates of strongyloidiasis in Africa, in some
regions of South and Central America, in Southeast Asia, and
in some regions of Europe have been reported as 0.1%–91.8%,
1.0%–83.3%, 6.6%–29.8%, and 1.4%–28%, respectively (2–7).
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In Turkey, the prevalence of strongyloidiasis
varies between 0% and 4.4% based on routine stool
examinations. Depending on these limited data,
strongyloidiasis commonly occurs in the Black Sea,
Marmara, Central Anatolia, and East Anatolia regions and
regions that have a temperate climate in Turkey such as the
Mediterranean region (8–16). In addition, some reports
state that strongyloidiasis in Turkey has been reported
in a patient with celiac disease, a patient with Behçet
disease, and patients taking corticosteroids (17–20).
However, a comprehensive study has not been conducted
in immunocompromised patients to determine the risk of
hyperinfection or disseminated strongyloidiasis.
Therefore, we aimed to investigate the presence of
strongyloidiasis in immunocompromised patients for the
first time in Turkey. During the study, serum and stool
samples were collected from 108 immunocompromised
patients who were admitted to Ege University Medical
School in İzmir, located in western Turkey. Serum samples
were analyzed by ELISA and the presence of the 18S rRNA
gene of S. stercoralis was detected in stool samples by realtime PCR.
2. Materials and methods
2.1. Ethics statement and patient samples
The study was approved by the Research Ethics Committee
of Ege University Medical School (Approval number: 132/15). The written informed consent form was obtained
from all study participants or their legal guardians.
No participants were under legal age. In addition,
demographic, clinical, and epidemiological data were
collected.
A total of 108 stool and serum samples were collected
between April 2013 and December 2013 from patients
with chronic renal failure (n: 28) or renal transplantation
patients (n: 80) admitted to Ege University Medical School.
2.2. Microscopy
All stool samples collected from 108 immunocompromised
patients were initially examined by phase contrast
microscopy (Nikon, Japan). Thereafter, DNA extraction
was performed on the samples.
2.3. Strongyloides IgG-ELISA
IgG antibodies against S. stercoralis were investigated in
the serum of 108 patients using a Strongyloides IgG-ELISA
kit (DRG, Germany) according to the manufacturer’s
protocol. Briefly, 100 µL of each serum at dilution of 1/64
was added to microtiter plates coated with S. stercoralis
antigen, incubated for 10 min at room temperature, and
washed three times. The positive and negative control
serum of the kit was applied directly without dilution.
Then all wells were probed by conjugate provided with
the kit, incubated 5 min at room temperature, and washed
three times. Bound antibodies were visualized after the
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substrate provided with the kit was added to each well
and incubated 5 min at room temperature. Finally, the
reaction was stopped by adding 100 µL of 0.5 M H2SO4
stop solution and the results were evaluated in a microtiter
plate reader (Bio-Tek EL x 808, USA) at 450 nm. The test
results were interpreted according to the manufacturer’s
instructions and a serum sample was considered positive
if the OD value was >0.200.
2.4. DNA isolation and real-time PCR
DNA was isolated from stools by QIAamp DNA stool
mini kit (Qiagen, USA) according to the manufacturer’s
protocol. During DNA isolation, 200 mg stools were used
and samples were eluted with 200 µL of elution buffer.
Real-time PCR targeting the 18S rRNA gene
of S. stercoralis (GenBank: AF279916) was performed
as described previously (21). Briefly, the primers used
for amplification of the 101 bp 18S rRNA gene fragment
were 5’-GAATTCCAAGTAAACGTAAGTCATTAGC-3’
(28
nt,
forward
primer)
and
5’-TGCCTCTGGATATTGCTCAGTTC-3’
(23
nt,
reverse primer). The hydrolysis probe was FAM-5’ACACACCGGCCGTCGCTGC-3’-BHQ (25 nt). Each
20 µL of PCR mix included 4 µL of patient DNA template
or controls, 1X Taqman Hydrolysis Probe mix (Roche),
0.06 µM each primer, probe 0.1 µM, 2.5 µg of BSA (2
mg/mL). PCR amplification reactions were performed
using the following calculated control protocol: 10 min
preincubation step at 95 °C, followed by 45 cycles of 10 s at
95 °C, 40 s at 60 °C, and 1 min at 72 °C.
S. stercoralis 18S rRNA gene fragment, which has
101 bp size, was isolated by the above primers and
amplification reaction and inserted into pCR 2.1-TOPO
plasmid (Invitrogen, USA) according to the manufacturer’s
protocol. This resulting plasmid containing the 101 bp
target gene was sequenced and used as positive control
plasmid. Distilled water was used as negative control.
3. Results
Among the 108 patients, 80 of them had undergone renal
transplantation and were under immune suppression
and the remaining 28 patients had chronic renal failure
and receiving hemodialysis. Out of the 28 chronic renal
failure patients, 4 of them had taken immunosuppressive
treatment. The median age of patients was 44.5 ± 14.3
years (range: 18–77 years) with most being male (n = 63;
58.33%); there were 45 females (41.66%).
Out of the 108 patients, 61 had some accompanying
disease in addition to chronic renal failure or renal
transplantation. While 20 had type II diabetes mellitus
(DM), 38 had hypertension and hyperlipidemia, and three
had coronary heart disease.
During sample collection, some clinic symptoms
were observed in 96 patients: 34 with high fever, 30 with
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diarrhea, 20 with cough, and 12 with sputum problem. In
addition, leukocytosis was detected in 18 patients, while
leucopenia and eosinophilia were present in five and
10 patients, respectively. The risk factors for acquiring
strongyloidiasis such as walking barefoot on soil was
present in all patients (100%), farming (40.7%), and
travelling to temperate regions (21.3%).
Stool samples belonging to the 108 patients were
examined by direct microscopy and none of them
contained the parasite, egg, or larvae of S. stercoralis.
Strongyloidiasis was detected in only one patient by realtime PCR and the patient was also seropositive by ELISA.
The patient was born in central Anatolia and had been
living in İzmir for 30 years. The patient had type II DM
and was being followed up for tuberculosis arthritis. Renal
transplantation of this patient was performed in 2001. In
addition, the patient had a history of walking barefoot on
soil but no clinical symptoms. After diagnosis, the patient
was treated twice with albendazole (400 mg/day for 3 days)
at 2-week intervals. Follow up real-time PCR and direct
microscopy of the stool sample were negative. The patient
became seronegative 6 months after initial diagnosis.
Overall, the prevalence of strongyloidiasis in this small
group of patients who were at risk of strongyloidiasis was
0.92%.
4. Discussion
Infections depending on intestinal parasites are still an
important public health problem in developing as well as
developed countries. Turkey is a developing country where
it presents an appropriate position for parasitic diseases
because of its geographic and socioeconomic conditions
and climate.
S. stercoralis is one of the most important intestinal
parasites because it can cause life-threatening infection
in immunocompromised individuals. Chronic infection
depending on S. stercoralis is commonly asymptomatic and
eosinophilia sometimes occurs. However, autoinfection
in particularly immunocompromised individuals can
cause dissemination or hyperinfection, which have high
mortality rates (4,22). Thus, screening for strongyloidiasis
in this group of patients is necessary before starting
immune suppressing treatment.
In Turkey, a few studies have been conducted to
detect the frequency of strongyloidiasis in humans and
it is reported that frequency range varies between 0%
and 4.4% (8). In a study conducted in Adana, 0.27% of
731 hospitalized patients were diagnosed positive for
strongyloidiasis using fecal examination methods (9). In
addition, positivity rates of strongyloidiasis in patients
presenting to a parasitology laboratory for stool routine
examination were 0.94%, 0.22%, 0%, 4.4%, 0.04%, 0.006%,
0.08%, 0.4%, and 0% in Hatay, Adana, İçel, Samsun, Ankara,

Bursa, Van, Eskişehir, and Diyarbakır, respectively (10–
16). In addition, some common properties of these studies
are as follows: patients at risk for strongyloidiasis are not
selected, only microscopic stool examination is used for
diagnosis, and finally all positive results detected in these
studies were detected during stool routine examinations.
In the present study, we aimed to study the prevalence
of strongyloidiasis in immunocompromised patients
who also have risk factors such as walking barefoot on
soil, farming, and travelling to temperate regions. To
investigate strongyloidiasis, ELISA and real-time PCR
were performed on serum and stool samples of all patients.
Real-time PCR was used to investigate the presence of the
18S rRNA gene of S. stercoralis instead of microscopy
because PCR methods show excellent sensitivity and
specificity compared to microscopic methods (21,23). In
addition, ELISA, detecting anti-S. stercoralis antibodies in
serum samples of patients, was used in combination with
real-time PCR to support and increase the positivity.
As a result, the 18S rRNA gene of S. stercoralis and
anti-S. stercoralis antibodies were detected only in one
patient’s samples (0.92%). This patient had type II DM
and was being followed up for tuberculosis arthritis.
Renal transplantation of this patient was performed in
2001 during treatment with everolimus (2.5 mg/day),
mycophenolate (1080 mg/day) and prednisolone (16
mg/day) for immunosuppression. As the patient was
diagnosed with strongyloidiasis, albendazole treatment
was initiated. During the follow up of the patient, PCR
and direct microscopy of stool sample became negative
and anti-S. stercoralis IgG antibodies was not detected 6
months after the initial diagnosis. The seronegativity after 6
months may be because of the treatment of active infection
and reduction in the total antibody amount due to the
continuous immunosuppression of the patient. Another
reason for the seronegativity may be the false negative
result obtained during the analyses of the follow-up serum
sample or a false positive result in the initial analyses of the
serum sample as detected by commercial ELISA kit, which
can be regarded as a limitation of the study.
In Brazil, S. stercoralis was investigated in stool and
serum samples of patients with type II DM (n: 78) and
controls without type II DM (n: 42). S. stercoralis was
detected in the stools of 3 patients with type II DM but not
detected in the control group. Moreover, anti-S. stercoralis
antibody was detected in 18 (23%) of 78 patients with
type II DM and 3 (7.1%) of 42 control patients without
type II DM, which was statistically significant (P < 0.05).
Interestingly, the S. stercoralis positivity in patients
with HbA1c ≤ 7 was 14% and with HbA1c > 7 was 9%.
Altogether, this study indicated that there was a possible
association between positive S. stercoralis serology and
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diabetes (24). Similarly, our S. stercoralis positive patient’s
HbA1c was 6.2, which supports the finding reported by
Mendonça et al. (24).
Molecular methods offer higher sensitivity and
specificity for the detection of parasitic infections in stool
samples (21,23). In a previous study, the sensitivity and
specificity of a real-time PCR method detecting the 18S
rRNA gene of S. stercoralis were determined in comparison
with agar plate culture, formalin ethyl acetate, and Harada
Mori microscopy techniques. Analysis of 231 stool
samples from patients at risk of strongyloidiasis showed
that the sensitivity and specificity of real-time PCR were
93.8% and 86.5%, respectively (25). In another similar
study, the 18S rRNA gene of S. stercoralis was investigated
by real-time and conventional PCR and compared with
other parasitological methods such as the Lutz method,
Rugai method, and agar-plate culture. Both molecular
methods (real-time and conventional PCR) on 100 stool
samples were more sensitive and specific compared to
other methods. The sensitivity and specificity of real-time
PCR were 90% and 85.7%, respectively (23). As a result,
molecular methods having high sensitivity and specificity

can be a more effective tool to diagnose strongyloidiasis.
In our study, the real-time PCR method detecting the
18S rRNA gene of S. stercoralis successively detected
strongyloidiasis in one seropositive patient’s stool sample.
The detection of a strongyloidiasis case during the
screening of a group of immunocompromised patients
enabled us to implement timely treatment of the patient.
The accumulated epidemiological data and the result
of this study show that strongyloidiasis does not seem
to be a major health problem in Turkey. Detecting one
strongyloidiasis positive patient among 108 patients is the
limitation of this study. More systematic studies covering
larger patient groups from the whole of Turkey, especially
the regions with higher incidence of strongyloidiasis, may
be performed to overcome this limitation. In addition, our
results support the use of molecular techniques for the
diagnosis of strongyloidiasis.
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